Industry News

Juno Therapeutics, Inc. between June 4, 2016 and July 7, 2016, inclusive. If you purchased or acquired Juno securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than September 12, 2016. A lead plaintiff is a representative party who..."/>
JUNO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Juno Therapeutics, Inc.
Agenus Inc., an immuno-oncology company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.. “In the second quarter, we made important advances in the clinic, saw external validation of our immuno-oncology agents and strategy and..."/>
Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
ViewRay, Inc., makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that the company's MRIdian ® System is the focus of 40 abstracts selected by the American Association of Physicists in Medicine for presentation during their 2016 Annual Meeting. AAPM is the largest association of medical physicists in the world and this year's meeting will be held July 31- August 4 in Washington, DC."/>
Leading Medical Physics Meeting to Feature 40 Presentations on ViewRay's MRIdian System
ANI Pharmaceuticals, Inc. announced today that the Company plans to release its second quarter and year-to-date 2016 financial results on Thursday, August 4, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com. Arthur S. Przybyl, President and Chief Executive Officer, and Stephen P. Carey, Vice..."/>
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results
Moleculin Biotech, Inc.,, a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a patented prodrug of a glucose decoy known as "2- DG", and termed by the Company as WP1122 was presented during a scientific session at the 28 th Annual..."/>
Moleculin Announces Data on WP1122 Presented at the 28th Annual International Carbohydrate Symposium
HCA Holdings, Inc. today announced financial and operating results for the second quarter ended June 30, 2016.. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160728005257/en/."/>
HCA Reports Second Quarter 2016 Results
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia. Data from the study are expected in 2017.. “Many adult patients with XLH have substantial disability, pain and stiffness due to complications from their disease, and..."/>
Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH)
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will release financial results and business updates for the second quarter of 2016 on Thursday, August 4, 2016. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.. The live call may be accessed by..."/>
Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016
Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2016 on August 11, 2016 before the market opens.. Histogenics’ management will host a conference call on Thursday, August 11, 2016 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks."/>
Histogenics Corporation to Announce Second Quarter 2016 Financial Results on August 11, 2016
International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson’ s Disease. The operation took place at The Royal Melbourne Hospital in..."/>
International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
Aytu BioScience, Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that it has entered into a $10.5 million common stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor. Upon execution of the agreement, LPC initially purchased 133,690 shares of common stock for $500,000. Thereafter, and pursuant to a..."/>
Aytu BioScience, Inc. Announces Common Stock Purchase Agreement for up to $10.5 Million
Masimo announced today that University Hospitals Geneva Medical Center, a Critical Access Hospital in Geneva, Ohio, is building a hospital-wide wireless monitoring and clinician notification system using Masimo Patient SafetyNet™* in conjunction with Masimo Root ® with Radius-7 ® and Masimo Radical-7 ®. UH Geneva is part of University Hospitals, based in Cleveland, Ohio. This Smart News Release features multimedia."/>
Leading Ohio Critical Access Hospital Adopts Masimo Root® with Radius-7®, Radical-7®, and Patient SafetyNet™ to Create Hospital-Wide Wireless Monitoring and Clinician Notification System
KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 36 th Annual Growth Conference being held August 10-11, 2016, at the InterContinental Boston Hotel.. Details of KemPharm's presentation are as follows:. Date: Thursday, August 11, 2016 Time:..."/>
KemPharm to Present at Canaccord Genuity 36th Annual Growth Conference
Fibrocell Science, Inc. will report financial results for the second quarter ended June 30, 2016 and recent operational highlights on Thursday, August 4, 2016, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’ s remarks.."/>
Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
HeartWare International, Inc., a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced total revenue of $68.7 million for the quarter ended June 30, 2016, compared to $73.6 million for the same period in 2015 and $55.1 million for the first quarter of 2016. Total revenue decreased approximately 7% year-over-year, which is..."/>
HeartWare International Reports $68.7 Million In Second Quarter 2016 Revenue
Five Star Quality Care, Inc. today announced that it will issue a press release containing its second quarter 2016 financial results before the Nasdaq opens on Thursday, August 4, 2016. Eastern Time that morning, President and Chief Executive Officer Bruce Mackey, Chief Financial Officer Rick Doyle and Chief Operating Officer Scott Herzig will host a conference call to discuss these results. The conference call telephone number is 329-4332. Participants..."/>
Five Star Quality Care, Inc. Second Quarter 2016 Conference Call Scheduled for Thursday, August 4th
Diplomat Pharmacy, Inc. is recognizing World Hepatitis Day with a campaign to raise awareness of the disease and honor patients who have felt its effects. World Hepatitis Day occurs annually July 28.. Meet Jacque: Conquering Hepatitis as a Diplomat Patient."/>
Diplomat to Recognize Patients with World Hepatitis Day Campaign
RTI Surgical, Inc., today publishes an open letter following the company's July 27 earnings warning, its fourth in three years. Curtis M. Selquist Chairman RTI Surgical, Inc. 11621 Research Circle Alachua, FL 32615. Congratulations on your victory against Krensavage Asset Management LLC and its efforts to protect the shareholder through our failed proxy fight."/>
Krensavage Poses Questions to RTI Surgical in Open Letter
CAS Medical Systems, Inc., a leader in medical devices for non-invasive patient monitoring, announces that it will report financial results for the second quarter of 2016 on Thursday, August 4, 2016, prior to the market’ s opening. Management will host a conference call to discuss these results and answer questions at 10:00 a.m. Eastern time that day.. Conference call dial-in information is as follows:."/>
CASMED to Report Second Quarter 2016 Financial Results and Hold Conference Call on August 4
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016 financial results and provide a company update on Thursday, August 4, 2016. Karyopharm’ s management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 4, 2016 to discuss the financial results and recent business developments.. To access the conference call, please dial 437-4406 or 756-4292..."/>
Karyopharm to Report Second Quarter 2016 Financial Results on August 4, 2016
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2016, at 4:30 p.m. ET to report second quarter 2016 financial results and provide a corporate update.. To participate in the..."/>
Cara Therapeutics to Announce Second Quarter 2016 Financial Results on August 4, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology835 Articles
Financials815 Articles
Consumer Discretionary692 Articles
Industrials536 Articles
Health Care523 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.